Molecular Therapy · 2017 · 280 citations · 44 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyPancreatic CancerTumor Microenvironment ModulationTumor-associated AntigensAdaptive Antitumor ImmunityCytokine AntagonismImmunogenicity Of Tumor AntigensImmunosuppressive MicroenvironmentT Cell Receptor-engineered T CellsT-cell Responses To Tumor AntigensTumor Antigen ImmunogenicityTumor Antigen Recognition
The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic expression of chimeric antigen receptors (CARs) has produced tumor responses, even in patients with refractory diseases. To target pancreatic cancer, we generated CAR T cells directed against prostate stem cell antigen (PSCA) and demonstrated specific tumor lysis. However, pancreatic tumors employ immune evasion strategies such as the production of inhibitory cytokines, which limit CAR T cell persistence and function. Thus, to protect our cells from the immunosuppressive cytokine IL-4, we generated an inverted cytokine receptor in which the IL-4 receptor exodomain was fused to the IL-7 receptor endodomain (4/7 ICR). Transgenic expression of this molecule in CAR-PSCA T cells should invert the inhibitory effects of tumor-derived IL-4 and instead promote T cell proliferation. We now demonstrate the suppressed activity of CAR T cells in tumor-milieu conditions and the ability of CAR/ICR T cells to thrive in an IL-4-rich microenvironment, resulting in enhanced antitumor activity. Importantly, CAR/ICR T cells remained both antigen and cytokine dependent. These findings support the benefit of combining the 4/7 ICR with CAR-PSCA to treat pancreatic cancer, a PSCA-expressing tumor characterized by a dense immunosuppressive environment rich in IL-4.
44
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter, Bruce L. Levine, Michael Kalos et al. · New England Journal of Medicine · 2011 · 3.5K citations · Full text
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp, Michael Kalos, David M. Barrett et al. · New England Journal of Medicine · 2013 · 3.5K citations · Full text